Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlotta Liljebris

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Journal of Organic Chemistry|June 14, 1996
Regio- and Stereoselective Reactions of 17-Phenyl-18,19,20-trinorprostaglandin F(2)(alpha) Isopropyl EsterCharlotta Liljebris, Björn M. Nilsson, Bahram Resul, et al.
Clinical Pharmacology in Drug Development|May 29, 2024
Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology PlatformHans Lennernäs, Magnus Brisander, Charlotta Liljebris, et al.
Journal of Clinical Pharmacology|December 27, 2024
Severe Impact of Omeprazole Timing on pH-Sensitive Dasatinib Absorption: Unveiling Substantial Drug-Drug InteractionPer Andersson, Magnus Brisander, Charlotta Liljebris, et al.
Journal of Medicinal Chemistry|April 19, 2002
Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activityCharlotta Liljebris, Scott D Larsen, Derek Ogg, et al.
European Journal of Haematology|July 28, 2023
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactionsGunnar Larfors, Per Andersson, Gérald Jesson, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 30, 2004
Oxidation of protein tyrosine phosphatases as a pharmaceutical mechanism of action: a study using 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dioneCharlotta Liljebris, Pawel Baranczewski, Eva Björkstrand, et al.
Bioorganic & Medicinal Chemistry|August 2, 2002
Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B)Charlotta Liljebris, Jessica Martinsson, Lars Tedenborg, et al.
British Journal of Clinical Pharmacology|February 18, 2026
Formulation breakthroughs driving broader tyrosine kinase useHans Lennernäs, Gerald Jesson, Charlotta Liljebris, et al.
Journal of Medicinal Chemistry|January 25, 2002
Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1BScott D Larsen, Tjeerd Barf, Charlotta Liljebris, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Organic Chemistry|June 14, 1996
Regio- and Stereoselective Reactions of 17-Phenyl-18,19,20-trinorprostaglandin F(2)(alpha) Isopropyl EsterCharlotta Liljebris, Björn M. Nilsson, Bahram Resul, et al.
Clinical Pharmacology in Drug Development|May 29, 2024
Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology PlatformHans Lennernäs, Magnus Brisander, Charlotta Liljebris, et al.
Journal of Clinical Pharmacology|December 27, 2024
Severe Impact of Omeprazole Timing on pH-Sensitive Dasatinib Absorption: Unveiling Substantial Drug-Drug InteractionPer Andersson, Magnus Brisander, Charlotta Liljebris, et al.
Journal of Medicinal Chemistry|April 19, 2002
Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activityCharlotta Liljebris, Scott D Larsen, Derek Ogg, et al.
European Journal of Haematology|July 28, 2023
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactionsGunnar Larfors, Per Andersson, Gérald Jesson, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 30, 2004
Oxidation of protein tyrosine phosphatases as a pharmaceutical mechanism of action: a study using 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dioneCharlotta Liljebris, Pawel Baranczewski, Eva Björkstrand, et al.
Bioorganic & Medicinal Chemistry|August 2, 2002
Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B)Charlotta Liljebris, Jessica Martinsson, Lars Tedenborg, et al.
British Journal of Clinical Pharmacology|February 18, 2026
Formulation breakthroughs driving broader tyrosine kinase useHans Lennernäs, Gerald Jesson, Charlotta Liljebris, et al.
Journal of Medicinal Chemistry|January 25, 2002
Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1BScott D Larsen, Tjeerd Barf, Charlotta Liljebris, et al.
Pageof 1